REZETAMIG
UNII M8FA2JKW5P

Substance Identification & Data

This profile provides standardized clinical and technical data for Rezetamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) M8FA2JKW5P.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2795115-07-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

M8FA2JKW5P

CAS Registry Number

2795115-07-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

REZETAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C178408

National Cancer Institute reference terminology for clinical and research data.

INN ID

12767

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Rezetamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Rezetamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Rezetamig

Common Names & Synonyms

Immunoglobulin G4, anti-(human CD3 antigen) (recombinant human monoclonal JNJ-75348780 γ4-chain), disulfide with recombinant human monoclonal JNJ-75348780 κ chain, (229→126′),(232→129′)-bis(disulfide) with immunoglobulin, anti-(human sialic acid-binding Ig-like lectin 2) (recombinant human single-domain VHH fragment)

gamma4 heavy chain anti-CD3E Homo sapiens (1-450) [VH (Homo sapiens IGHV3-9*01 (98.0%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10,G4v4 CH2 A1.3, A1.2,G4v32 CH3 W22 (knob) (CH1 (124-221), hinge 1-12 S10>P (231) (222-233), CH2 F1.3>A (237), L1.2>A (238), L92 (312) (234-343), CH3 T22>W (369) (344-448), CHS (449-450)) (124-450)], (137-214')-disulfide with kappa light chain anti-CD3E Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (100%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101(191') (108'-214')], gamma4 heavy chain anti-CD22 Homo sapiens VH-h-CH2-CH3 (1''-347'') [VH(Homo sapiens IGHV4-39*01 (91.9%) -(IGHD) -IGHJ1*01 W118>R (108'')(85.7%), CDR-IMGT [10.7.10] (26''-35''.53''-59''.98''-107'')) (1''-118'')-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10,G4v4 CH2 A1.3, A1.2,G4v33 CH3 S22, A24, V86 (hole) (hinge 1-12 S10>P (128'') (119''-130''), CH2 F1.3>A (134''), L1.2>A (135''), L92 (209'') (131''-240''), CH3 T22>S (266''),L24>A (268''), Y86>V (307'') (241''-345''), CHS (346''-347'')) (119''-347'')]; dimer (229-126'':232-129'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

immunoglobulin half G4-kappa_G4(VH-h-CH2-CH3), anti-[Homo sapiens CD3E (CD3 epsilon)] and anti-[Homo sapiens CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)], Homo sapiens monoclonal antibody, bispecific, bivalent

rezetamig [INN]